Drug Trial Radar · NCT06974929
A Clinical Study of HRS-6209 Combined With Other Treatment Regimens in Patients With Breast Cancer
Last checked: Nov 20, 2026Latest source record: Jun 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
May 22, 2025
Primary completion
Dec 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 16, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study to evaluate the safety, tolerability, and pharmacokinetic characteristics of HRS-6209 combined with other treatment regimens in breast cancer patients, and preliminarily observe its anti-tumor efficacy.
Conditions
- Breast Cancer
Interventions
HRS-6209 CapsulesDrug
Oral HRS-6209 capsules.
Letrozole TabletsDrug
Oral Letrozole tablets.
HRS-2189 TabletsDrug
HRS-2189 tablets.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-limiting toxicity (DLT)Time frame: 28 days after the first dose.
- Maximum tolerated dose (MTD)Time frame: 28 days after the first dose.
- Recommended phase II dose (RP2D)Time frame: 28 days after the first dose.
- Adverse events (AEs)Time frame: About 1 year.
- Serious adverse events (SAEs)Time frame: About 1 year.
- Objective response rate (ORR)Time frame: About 1 year.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.